^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SOX4 (SRY-Box Transcription Factor 4)

    i
    Other names: SOX4, SRY-Box Transcription Factor 4, SRY (Sex Determining Region Y)-Box 4, Transcription Factor SOX-4, SRY-Box 4, Ecotropic Viral Integration Site 16, SRY-Related HMG-Box Gene 4, CSS10, EVI16
    Associations

    News

    Trials
    3d
    Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression. (PubMed, Adv Sci (Weinh))
    Notably, the AXL inhibitor Bemcentinib effectively suppressed CML-BP progression in both in vivo and in vitro models. Collectively, our findings establish SE-driven SOX4 and SMAD3 as key regulators in CML-BP and identify Bemcentinib as a promising therapeutic strategy.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • LPCAT1 (Lysophosphatidylcholine Acyltransferase 1) • SMAD3 (SMAD Family Member 3) • SOX4 (SRY-Box Transcription Factor 4)
    |
    bemcentinib (BGB324)
    17d
    Single-cell and machine learning integration reveals OS-driven CCND1 promotes an aggressive phenotype in papillary thyroid carcinoma. (PubMed, Front Immunol)
    Conversely, SOX4 also acts as an oncogene, and TFF3 as a potential tumor suppressor, both linked to OS. Targeting CCND1 and its OS-mediated regulatory pathways offers a promising therapeutic strategy for PTC.CCND1, oxidative stress, papillary thyroid carcinoma, single-cell RNA sequencing, SOX4, TFF3.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • CCND1 (Cyclin D1) • TFF3 (Trefoil factor 3) • SOX4 (SRY-Box Transcription Factor 4)
    19d
    TGFβ signaling promotes cell cycle progression and resistance to the CDK4/6 inhibitor palbociclib through SOX4 transcriptional modulation in breast cancer cells. (PubMed, Cell Death Dis)
    Validating the genome-wide analyses, we found that resistance of breast cancer cells to the CDK4/6 inhibitor palbociclib conferred by TGFβ stimulation was functionally dependent on SOX4. Collectively, our findings reveal an apparent oncogenic function of TGFβ in promoting cell cycle progression and drug resistance through SOX4, highlighting the pro-tumorigenic role of TGFβ signaling in breast cancer progression.
    Journal
    |
    HRAS (Harvey rat sarcoma viral oncogene homolog) • SMAD3 (SMAD Family Member 3) • SOX4 (SRY-Box Transcription Factor 4)
    |
    Ibrance (palbociclib)
    20d
    The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. (PubMed, Cell Death Dis)
    Our study unveiled the potentiating effects of SOX4/AC093895.1/miR-1253/SOX4 on ovarian cancer cell survival, migration, and invasion. AC093895.1 may be a promising patient prognostic biomarker and therapeutic candidate.Created with BioRender.com.
    Journal
    |
    SOX4 (SRY-Box Transcription Factor 4)
    23d
    SOX4 drives the differentiation of CD4+T cells toward an immunosuppressive phenotype (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
    Moreover, SOX4 overexpression enhanced ATP production and the levels of mitochondrial respiratory chain complexs while reducing ROS and mtROS levels in CD4+T cells, with no significant change in mitochondrial mass. Conclusion We demonstrate that SOX4 induces a plastic Treg-like state in CD4+T cells, modulates the expression of key molecules associated with Treg suppressive function, and enhances their oxidative phosphorylation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • SMAD4 (SMAD family member 4) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • TNFRSF4 (TNF Receptor Superfamily Member 4) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • YBX1 (Y-Box Binding Protein 1) • IL4 (Interleukin 4) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3) • SOX4 (SRY-Box Transcription Factor 4) • TCF4 (Transcription Factor 4)
    26d
    The castration-resistant prostate cancer-associated SNP rs11067228 facilitates neuroendocrine differentiation through an enhancer-mediated chromatin interaction with SRRM4. (PubMed, Int J Biol Sci)
    Moreover, site-directed mutation of the rs11067228 non-risk G to the risk A allele enabled binding of the transcription factor SOX4, activating candidate target gene expression. Taken together, our findings indicated that the rs11067228-associated enhancer modulates expression of SRRM4 via allele-specific long-range chromatin interactions, thereby governing PCa drug resistance and neuroendocrine differentiation.
    Journal
    |
    SRRM4 (Serine/Arginine Repetitive Matrix 4) • SOX4 (SRY-Box Transcription Factor 4)
    2ms
    SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. (PubMed, Cell Death Dis)
    Targeting STAT6 or MTHFD2 suppressed tumor growth in TKIs-resistant patient-derived xenograft models. Collectively, our findings identify the SOX4-STAT6-MTHFD2 axis as a critical driver of HCC progression and therapeutic resistance, offering a promising target for intervention in refractory HCC.
    Journal • IO biomarker
    |
    STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2) • SOX4 (SRY-Box Transcription Factor 4)
    2ms
    Single-cell RNA sequencing reveals heterogeneity among AT2 epithelial cells in the lung adenocarcinoma microenvironment. (PubMed, Front Immunol)
    This comprehensive single-cell analysis increases our understanding of AT2 cells molecular and dynamics of metastatic lung cancer. In summary, single-cell RNA profiling of LUAD offers valuable prognostic insights based on AT2 cell types and identifies potential biomarkers for therapeutic responses, aiding the future development of LUAD treatment strategies.
    Journal
    |
    ERBB4 (erb-b2 receptor tyrosine kinase 4) • SPP1 (Secreted Phosphoprotein 1) • SLC2A1 (Solute Carrier Family 2 Member 1) • SOX4 (SRY-Box Transcription Factor 4) • TEAD1 (TEA Domain Transcription Factor 1)
    2ms
    Constructing a prognostic signature of tumor-associated B lymphocytes in hepatocellular carcinoma via machine learning integration. (PubMed, Sci Rep)
    External validation was performed in publicly accessible HCC cohorts with individual-level outcomes; prospective validation in additional HCC-specific immunotherapy cohorts will further strengthen clinical relevance. TABLS is a promising prognostic biomarker for HCC, with potential clinical applications in therapy selection.
    Journal • IO biomarker
    |
    SOX4 (SRY-Box Transcription Factor 4) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    3ms
    RBP2 promotes gastric cancer cell migration by acting as a competitive endogenous RNA to upregulate SOX4 via sponging miR-212-3p. (PubMed, Sci Rep)
    Furthermore, we showed that the 3'UTR of RBP2 promotes gastric cancer cell migration by enhancing the expression of both RBP2 and SOX4. Collectively, our findings reveal the oncogenic function of the RBP2 3'UTR and delineate a novel RBP2-miR-212-3p-SOX4 regulatory axis, providing mechanistic insights with potential diagnostic and therapeutic relevance for gastric cancer.
    Journal
    |
    RBP2 (Retinol Binding Protein 2) • SOX4 (SRY-Box Transcription Factor 4)
    3ms
    Neuro-oncological ventral antigen 1 regulates liver cancer stem cell properties and Lenvatinib resistance via targeting SOX4. (PubMed, Cancer Cell Int)
    Moreover, knocking down SOX4 could reverse the NOVA1 overexpression-mediated desensitization of HCC cells to Lenvatinib-induced cell apoptosis. In summary, this investigation indicates the essential role of NOVA1 self-renew of CSCs and tumorigenesis in the liver, suggesting it as an optimal HCC therapeutic target.
    Journal
    |
    SOX4 (SRY-Box Transcription Factor 4)
    |
    Lenvima (lenvatinib)
    3ms
    Evaluation of the correlativity of SOX4 and epithelial-mesenchymal transition markers expression in the prognosis of oral squamous cell carcinoma. (PubMed, Arch Oral Biol)
    In summary, our study identified SOX4, N-cadherin, TWIST1, E-cadherin, lymph node metastasis, and clinical staging as independent factors influencing the prognosis of OSCC. SOX4 promotes EMT, thereby influencing the progression and prognosis of OSCC.
    Journal
    |
    CDH1 (Cadherin 1) • SOX2 • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • SOX4 (SRY-Box Transcription Factor 4)